Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Marchetti

Showing results (301-310 of 450) with videos related to

Pageof 45
Sort By:
Critical Reviews in Oncology/Hematology|March 6, 2021
Second medical opinion in oncological settingMarco Maruzzo, Nicla La Verde, Antonio Russo, et al.
Rare Tumors|December 7, 2020
Primary squamous cell carcinoma of major salivary gland: "Sapienza Head and Neck Unit" clinical recommendationsSilvia Mezi, Giulia Pomati, Andrea Botticelli, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|October 1, 2014
Circulating tumor cells count predicts survival in colorectal cancer patientsAdriana Romiti, Salvatore Raffa, Roberta Di Rocco, et al.
BMC Cancer|April 17, 2024
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysisAlessio Cirillo, Daniele Marinelli, Umberto Romeo, et al.
Cell Death Discovery|July 6, 2021
H-Ras gene takes part to the host immune response to COVID-19Salvatore Sciacchitano, Andrea Sacconi, Claudia De Vitis, et al.
BMC Cancer|April 8, 2024
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysisAlessio Cirillo, Daniele Marinelli, Umberto Romeo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patientsStefano Cascinu, Gerardo Rosati, Guglielmo Nasti, et al.
Cancers|December 17, 2024
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a SignatureMarco Filetti, Mario Occhipinti, Alessio Cirillo, et al.
Frontiers in Oncology|August 16, 2024
Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patientsFrancesca Romana Di Pietro, Sofia Verkhovskaia, Rosa Falcone, et al.
Frontiers in Oncology|April 29, 2026
Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?Francesca Romana Di Pietro, Rosa Falcone, Sofia Verkhovskaia, et al.
Pageof 45

Showing results (301-310 of 450) with videos related to

Sort By:
Pageof 45
Critical Reviews in Oncology/Hematology|March 6, 2021
Second medical opinion in oncological settingMarco Maruzzo, Nicla La Verde, Antonio Russo, et al.
Rare Tumors|December 7, 2020
Primary squamous cell carcinoma of major salivary gland: "Sapienza Head and Neck Unit" clinical recommendationsSilvia Mezi, Giulia Pomati, Andrea Botticelli, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|October 1, 2014
Circulating tumor cells count predicts survival in colorectal cancer patientsAdriana Romiti, Salvatore Raffa, Roberta Di Rocco, et al.
BMC Cancer|April 17, 2024
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysisAlessio Cirillo, Daniele Marinelli, Umberto Romeo, et al.
Cell Death Discovery|July 6, 2021
H-Ras gene takes part to the host immune response to COVID-19Salvatore Sciacchitano, Andrea Sacconi, Claudia De Vitis, et al.
BMC Cancer|April 8, 2024
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysisAlessio Cirillo, Daniele Marinelli, Umberto Romeo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patientsStefano Cascinu, Gerardo Rosati, Guglielmo Nasti, et al.
Cancers|December 17, 2024
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a SignatureMarco Filetti, Mario Occhipinti, Alessio Cirillo, et al.
Frontiers in Oncology|August 16, 2024
Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patientsFrancesca Romana Di Pietro, Sofia Verkhovskaia, Rosa Falcone, et al.
Frontiers in Oncology|April 29, 2026
Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?Francesca Romana Di Pietro, Rosa Falcone, Sofia Verkhovskaia, et al.
Pageof 45